THERAPEUTIC CLASS
AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis
Liver biopsy is the recognized gold standard for liver fibrosis staging. The aspartate minotransferase to platelet ratio index (APRI) has been proposed as a noninvasive and readily available tool for the assessment of liver fibrosis in chronic hepatitis C (CHC).
This study aimed to validate, in a Mexican tertiary health care setting, the diagnostic usefulness of APRI in CHC, nonalcoholic fatty liver disease (NAFLD) and autoimmune hepatitis (AIH).
No other version available